CD86 and neoplasm: We then investigated the anti-tumor immune responses by evaluating the expression levels of CD3+, CD4+, and CD8+ T cells, as well as DC maturation (CD11c+, CD86, and CD80) in tumors (Fig. 6d and Supplementary Figs. S37–S40).